--- title: "ENVOY MEDICAL INC C/WTS 29/09/2028 (TO PUR COM) | 8-K: FY2025 Revenue: USD 241 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/280840063.md" datetime: "2026-03-27T20:03:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280840063.md) - [en](https://longbridge.com/en/news/280840063.md) - [zh-HK](https://longbridge.com/zh-HK/news/280840063.md) generator: "portal-rs" --- # ENVOY MEDICAL INC C/WTS 29/09/2028 (TO PUR COM) | 8-K: FY2025 Revenue: USD 241 K Revenue: As of FY2025, the actual value is USD 241 K. EPS: As of FY2025, the actual value is USD -1.23. EBIT: As of FY2025, the actual value is USD -20.68 M. ### Financial and Operational Highlights for 2025 #### Revenue - Net Revenue for ENVOY MEDICAL, INC. was $241 thousand for the year ended December 31, 2025, an increase from $225 thousand for the year ended December 31, 2024. This $16 thousand increase was primarily driven by sales of the Esteem® FI-AMEI implant and related replacement components . #### Operational Metrics - Cost of goods sold increased by $132 thousand to $874 thousand in 2025 from $742 thousand in 2024, mainly due to a $190 thousand rise in scrap and non-recurring expenses, partially offset by lower third-party fees of $77 thousand . - Research and development (R&D) expenses increased by $2,307 thousand, from $10,179 thousand in 2024 to $12,486 thousand in 2025, primarily reflecting additional clinical trial expenses during enrollment . - Sales and marketing expenses decreased by $514 thousand, from $1,734 thousand in 2024 to $1,220 thousand in 2025, mainly due to a reduction in legal fees for reimbursement work related to the Esteem FI-AMEI product . - General and administrative expenses increased by $1,105 thousand, from $6,826 thousand in 2024 to $7,931 thousand in 2025, primarily due to severance costs for the former Chief Financial Officer and increased consulting expenses . - Total costs and operating expenses for 2025 were $22,511 thousand, up from $19,481 thousand in 2024 . - Operating loss for 2025 was - $22,270 thousand, compared to - $19,256 thousand in 2024 . - Net loss for 2025 was - $23,756 thousand, compared to - $20,795 thousand in 2024 . - Comprehensive loss was - $23,753 thousand in 2025, compared to - $20,800 thousand in 2024 . #### Cash Flow - Net cash used in operating activities was - $18,201 thousand in 2025, compared to - $17,949 thousand in 2024 . - Net cash used in investing activities was - $179 thousand in 2025, compared to - $980 thousand in 2024 . - Net cash provided by financing activities was $16,633 thousand in 2025, compared to $20,198 thousand in 2024 . - Cash at the end of the year was $3,739 thousand in 2025, down from $5,483 thousand in 2024 . #### Balance Sheet Metrics - Total assets were $8,558 thousand as of December 31, 2025, a decrease from $11,538 thousand in 2024 . - Total liabilities were $20,325 thousand as of December 31, 2025, down from $30,380 thousand in 2024 . - ENVOY MEDICAL, INC. extinguished over $32 million in debt, strengthening its balance sheet . - Term loans payable (related party) were $0 thousand as of December 31, 2025, compared to $18,716 thousand in 2024 . - Total stockholders’ deficit was - $12,158 thousand in 2025, an improvement from - $18,842 thousand in 2024 . - The company strengthened its balance sheet with up to a $78 million public offering ($30 million received, $48 million potential from warrants) subsequent to year-end . #### Operational Achievements - ENVOY MEDICAL, INC. received FDA approval to expand its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant to its final stage based on promising three-month data . - The company completed the first set of activations in the final stage of the pivotal clinical study for its Acclaim® Cochlear Implant and achieved a six-month milestone with the first 10 patients in the trial . - Subsequent to year-end, ENVOY MEDICAL, INC. completed enrollment of a 56-patient U.S. pivotal trial for the fully implanted Acclaim® Cochlear Implant . - The company expanded its IP portfolio to 47 patents across North America, Europe, Asia, and Australia as of February 20, 2026 . #### Outlook / Guidance ENVOY MEDICAL, INC. is positioned for an exceptional start to 2026 due to a transformational capital raise and completed enrollment for its pivotal clinical trial . The company intends to continue gathering data and looks forward to submitting its PMA application to the FDA . This aims to revolutionize hearing health with fully implanted solutions . ### Related Stocks - [COCHW.US](https://longbridge.com/en/quote/COCHW.US.md) ## Related News & Research - [Zscaler (ZS) Is Down 5.1% After Issuing 2027 Guidance And Filing US$1.69 Billion Shelf Registration – Has The Bull Case Changed?](https://longbridge.com/en/news/298038986.md) - [McDonald's Stock (MCD) Hits 52-Week Low. Here's What's Holding Back the Burger Chain](https://longbridge.com/en/news/298057026.md) - [Lululemon's Comparable Sales Fell 9%. Can New CEO Heidi O'Neill Turn Things Around or Is the Brand Broken?](https://longbridge.com/en/news/298017136.md) - [KLA Corporation $KLAC Stock Holdings Lifted by Knollwood Investment Advisory LLC](https://longbridge.com/en/news/298021836.md) - [Premier Path Wealth Partners LLC Acquires 7,360 Shares of KLA Corporation $KLAC](https://longbridge.com/en/news/298020303.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**